Introduction {#S0001}
============

Cancer, the second major source of mortality in humans after cardiovascular diseases, remains a considerable health obstacle worldwide.[@CIT0001] Although substantial advances have been made with cancer-diagnosis tools and many chemotherapeutic agents are currently available as treatments, successful management of cancer remains a medical challenge. Because current cancer-chemotherapeutic agents show a lack of selectivity and can elicit multiple-drug resistance, there exists a constant need to derive newer and safer anticancer agents.[@CIT0002]--[@CIT0004]

Creating novel anticancer chemotherapeutic agents based on naturally occurring bioactive substances has been gaining increased interest.[@CIT0005],[@CIT0006] 2,3-Dioxindole (isatin, **I**, [Figure 1](#F0001){ref-type="fig"}) is a natural substance found in some plant species, which can also be present in humans, due to endogenous consumption. Compound **I** has a distinguished pharmacological profile and exhibits a wide spectrum of biological actions, including anti-oxidant,[@CIT0007] anti-inflammatory,[@CIT0008] anti-bacterial,[@CIT0009] and anticancer[@CIT0010],[@CIT0011] activities. The United States Federal Drug Administration approved sunitinib and nintedanib as isatin-bearing anticancer drugs,[@CIT0010],[@CIT0012] and many compounds with an isatin scaffold such as SU6668 and SU5416 have displayed outstanding anticancer activity.[@CIT0013]--[@CIT0015] Therefore, isatin-bearing drugs might exhibit extensive cytotoxicity against cancer cells. Figure 1Chemical structures of compounds **I, II**, and **5a--s.**

Indole (1*H*-benzo\[b\]pyrrole, **II**, [Figure 1](#F0001){ref-type="fig"}) has a bicyclic heterocycle scaffold that is widely distributed in animals, microbial hormones, and plants.[@CIT0016],[@CIT0017] It is considered to be a beneficial motif in drug-discovery programs because of its biodiversity, versatility, and anticancer activity.[@CIT0018]--[@CIT0021] Previous evidence suggests that myriad indole-based compounds exert anticancer activities through various mechanisms,[@CIT0022]--[@CIT0027] suggesting the possibility of using the indole scaffold in anticancer drugs. Notably, anticancer indole-based molecules target several pathways, such as those involving tubulin polymerization, DNA topoisomerase, histone deacetylase, proto-oncogenes, and serine/threonine (PIM) kinase.[@CIT0028]--[@CIT0031]

Screening the literature exposed that a number of bioactive molecules bear carbohydrazide moiety. They display a wide spectrum of biological activities including anticancer activity.[@CIT0032]--[@CIT0034]

Combining the structural features of two differing pharmacophores is an effective tactic in medicinal chemistry, as new bioactive, chemotherapeutic chemical entities characterized by a reduced risk of drug--drug interactions and improved anticancer profiles can be obtained.[@CIT0035]--[@CIT0037] Considering the structural characteristics of isatin and indole, merging these two bioactive moieties into a single compound through a carbohydrazide bridge is predicted to result in new promising anticancer leads. Accordingly, we aimed to synthesize and evaluate the in vitro antiproliferative activities of the molecular hybrids **5a--s**. The most active antiproliferative candidate **5m** was also examined in an in-depth pharmacological-profiling study to understand the potential mechanism whereby these compounds exert their antiproliferative effect.

Materials and Methods {#S0002}
=====================

Chemistry {#S0002-S2001}
---------

### General {#S0002-S2001-S3001}

The melting points of compounds **5a--s** were measured using the Gallenkamp melting point equipment and are presented as uncorrected values. Compounds **5a--s** were dissolved in DMSO-*d~6~* for nuclear magnetic resonance (NMR) measurements at 500 and 125 MHz for ^1^H and ^13^C, respectively, using a Bruker NMR spectrometer (Bruker, Reinstetten, Germany) at the Research Center (College of Pharmacy, King Saud University, Saudi Arabia). TMS was used as an internal standard for the NMR measurements. The measured chemical shifts are presented as δ-values in parts per million (ppm). Compounds **5a--s** were subjected to microanalyses at the Microanalysis Laboratory (Cairo University, Cairo, Egypt), and the results aligned well with the proposed structures (i.e., within ± 0.4% of the theoretical values). A 6120 LC/MS Agilent Quadrupole system with an electrospray-ionization(ESI) source (Agilent Technologies, Palo Alto, CA, USA) was used to obtain the mass spectra of compounds **5a--s**. Compound **3** and compounds **4a--n** were prepared as described previously.[@CIT0038]

### General Procedure for Synthesizing Carbohydrazides 5a--s {#S0002-S2001-S3002}

The acid hydrazide **3** (0.18 g, 1 mmol) was dissolved in absolute ethanol (15 mL), and the appropriate isatin derivative **4a--n** (1 mmol) was added to the stirred ethanolic solution containing drops of glacial acetic acid. The reaction mixture was refluxed under continuous stirring for 4 h, and then the hot alcoholic reaction mixture was filtered. The collected solids were re-crystallized from the ethanol/DMF mixture (3:1) to yield the corresponding target carbohydrazides **5a--s** with yields of 40 to 95%.

*N*′-\[(3*Z*)-2-Oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5a**): Yellow powder, melting point (m.p.) \> 300 °C (yield 89%); ^1^H NMR (DMSO-*d*~6~) ppm: 6.95 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.09--7.16 (m, 2H, H~ar.~), 7.29 (d, *J* = 7.0 Hz, 1H, H~ar.~), 7.42 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.51 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.61 (s, 1H, H~ar.~), 7.73 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.05 (d, *J* = 7.5 Hz, 1H, H~ar.~), 10.88 (s, 1H, NH), 11.69 (s, 1H, NH), 11.97 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 104.2, 111.1, 112.9, 116.1, 120.7, 122.3, 122.7, 123.2, 125.1, 127.2, 127.5, 129.3, 133.2, 137.6, 144.4 (C~ar.~, CH~ar.~, C=N), 160.9, 165.3 (2 × C=O); MS m/z: 303 \[M-H\]^--^.

*N*′-\[(3*Z*)-5-Bromo-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5b**): Yellow powder, m.p. \> 300 °C (yield 76%); ^1^H NMR (DMSO-*d*~6~) ppm: 6.90 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.09--7.14 (m, 1H, H~ar.~), 7.28 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.51 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.59 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.65 (s, 1H, H~ar.~), 7.73 (d, *J* = 8 Hz, 1H, H~ar.~), 8.34 (s, 1H, H~ar.~), 11.01 (s, 1H, NH), 11.87 (s, 1H, NH), 11.95 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 104.8, 108.6, 112.9, 113.8, 117.5, 120.7, 121.0, 122.8, 125.2, 127.5, 129.2, 135.2, 136.4, 137.7, 143.5 (C~ar.~ and CH~ar.~, C=N), 160.7, 164.8 (2 × C=O); MS m/z: 381 \[M-H\]^−^, 383 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-5-Chloro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5c**): Yellow powder, m.p. \> 300 °C (yield 91%); ^1^H NMR (DMSO-*d*~6~) ppm: 6.95 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.09--7.14 (m, 1H, H~ar.~), 7.27--7.32 (m, 1H, H~ar.~), 7.43--7.47 (m, 1H, H~ar.~), 7.51 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.66 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.22 (s, 1H, H~ar.~), 11.00 (s, 1H, NH), 11.86 (s, 1H, NH), 11.96 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm:102.1, 109.3, 112.4, 112.9, 117.1, 120.7, 122.8, 125.2, 126.2, 126.6, 127.5, 132.4, 137.6, 138.9, 143.0 (C~ar.~ and CH~ar.~, C=N), 163.5, 165.1 (2 × C=O); MS m/z: 337 \[M-H\]^−^; 339 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-5-Fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5d**): Yellow powder, m.p. \> 300 °C (yield 95%); ^1^H NMR (DMSO-*d*~6~) ppm: 6.93 (dd, *J* = 4, 8.5 Hz, 1H, H~ar.~), 7.10 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.25--7.30 (m, 2H, H~ar.~), 7.50 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.66 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.02 (d, *J* = 8.0 Hz, 1H, H~ar.~), 10.89 (s, 1H, NH), 11.79 (s, 1H, NH), 11.95 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 108.4, 111.8, 112.8, 112.9, 113.1, 114.3, 120.7, 120.9, 122.7, 122.8, 125.3, 125.5, 137.5, 139.1 (C~ar.~, CH~ar.~, C=N), 157.9 (C~1ʹ-F~, *J* = 235.0 Hz, C~ar.~), 163.7, 165.4 (2 × C=O); MS m/z: 321 \[M-H\]^--^.

*N*′-\[(3*Z*)-5-Methoxy-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5e**): Orange powder, m.p. \> 300 °C (yield 75%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.82 (s, 3H, OCH~3~), 6.86 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.02 (dd, *J* = 2.0, 8.5 Hz, 1H, H~ar.~), 7.09 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.28 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.51 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.63 (s, 1H, H~ar.~), 7.70--7.74 (m, 2H, H~ar.~), 10.69 (s, 1H, NH), 11.81 (s, 1H, NH), 11.95 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 56.3 (OCH~3~), 102.6, 111.6, 112.6, 112.9, 113.1, 116.4, 118.7, 120.7, 122.8, 125.1, 127.5, 137.5, 138.1, 154.9, 155.9 (C~ar.~, CH~ar.~, C=N), 163.8, 165.4 (2 × C=O); MS m/z: 333 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-Methyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5f**): Yellow powder, m.p. 258--260 °C (yield 41%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.23 (s, 3H, NCH~3~), 7.13 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.17--7.21 (m, 2H, H~ar.~), 7.28 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.47--7.53 (m, 2H, H~ar.~), 7.61 (s, 1H, H~ar.~), 7.73 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.09 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.76 (s, 1H, NH), 11.98 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 26.6 (NCH~3~), 109.8, 110.5, 113.1, 121.0, 122.8, 125.1, 125.4, 126.8, 127.4, 129.3, 132.0, 133.1, 137.6, 144.1, 145.4 (C~ar.~, CH~ar.~, C=N), 161.7, 163.9 (2 × C=O); MS m/z: 317 \[M-1\]^--^.

*N*′-\[(3*Z*)-5-Bromo-1-methyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5g**): Yellow powder, m.p. 291--293 °C (yield 63%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.21 (s, 3H, NCH~3~), 7.08--7.15 (m, 2H, H~ar.~), 7.28 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.51 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.63--7.68 (m, 2H, H~ar.~), 7.73 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.38 (s, 1H, H~ar.~), 11.93 (s, 1H, NH), 11.95 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 26.6 (NCH~3~), 111.6, 112.9, 114.5, 120.6, 122.8, 123.3, 125.2, 127.5, 128.9, 134.1, 135.0, 137.5, 138.1, 143.1, 144.5 (C~ar.~, CH~ar.,~ C=N), 161.4, 162.1 (2 × C=O); MS m/z: 395 \[M-H\]^−^, 397 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-5-Chloro-1-methyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5h**): Yellow powder, m.p. 292--294 °C (yield 82%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.22 (s, 3H, NCH~3~), 7.10 (d, *J* = 8.0, 1H, H~ar.~), 7.13 (d, *J* = 4.0 Hz, 1H, H~ar.~), 7.27--7.31 (m,1H, H~ar.~), 7.51 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.54 (dd, *J* = 8.5, 2.0 Hz, 1H, H~ar.~), 7.66 (s, 1H, H~ar.~), 7.73 (d, *J* = 8.0, 1H, H~ar.~), 8.26 (s, 1H, H~ar.~), 11.92 (s, 1H, NH), 11.95 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 26.6 (NCH~3~), 109.3, 111.1, 112.0, 112.9, 120.7, 122.8, 125.2, 126.3, 126.8, 127.5, 127.9, 132.2, 137.6, 142.7, 144.1 (C~ar.~, CH~ar.,~ C=N), 159.4, 161.5 (2 × C=O); MS m/z: 351 \[M-H\]^--^.

*N*′-\[(3*Z*)-5-Fluoro-1-methyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5i**): Yellow powder, m.p. 283--285 °C (yield 54%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.22 (s, 3H, NCH~3~), 7.09--7.14 (m, 2H, H~ar.~), 7.27--7.30 (m, 1H, H~ar.~), 7.37 (ddd, *J* = 2.5, 9.0, 9.0, 1H, H~ar.~), 7.51 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.67 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.07 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.86 (s, 1H, NH), 11.96 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 26.7 (NCH~3~), 109.4, 110.6, 113.1, 114.2, 115.7, 118.9, 120.7, 122.8, 125.2, 125.4, 127.5, 129.0, 137.6, 141.8 (C~ar.~, CH~ar.,~ C=N), 158.3 (C~1ʹ-F~, *J* = 235.6 Hz, C~ar.~), 161.8, 163.9 (2 × C=O);MS m/z: 335 \[M-H\]^--^.

*N*′-\[(3*Z*)-5-Methoxy-1-methyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5j**): Orange powder, m.p. 279--281 °C (yield 86%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.19 (s, 3H, NCH~3~), 3.84 (s, 3H, OCH~3~), 7.04 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.08--7.12 (m, 2H, H~ar.~), 7.27--7.30 (m, 1H, H~ar.~), 7.63 (s, 1H, H~ar.~), 7.66 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.72--7.77 (m, 2H, H~ar.~), 11.86 (s, 1H, NH), 11.96 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 26.6 (NCH~3~), 56.4 (OCH~3~), 110.2, 111.3, 112.9, 113.4, 115.8, 117.9, 120.7, 122.8, 125.1, 127.5, 129.2, 137.5, 139.2, 155.5 (C~ar.~, CH~ar.,~ C=N), 161.7, 163.9 (2 × C=O); MS m/z: 347 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-Benzyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5k**): Yellow powder, m.p. 249--251 °C (yield 56%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.02 (s, 2H, CH~2~), 7.06 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.10--7.13 (m, 1H, H~ar.~), 7.16--7.21 (m, 1H, H~ar.~), 7.28--7.32 (m, 2H, H~ar.~), 7.35--7.38 (m, 3H, H~ar.~), 7.42--7.45 (m, 2H, H~ar.~), 7.51 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.65 (s, 1H, H~ar.~), 7.74 (d, *J* = 7.5 Hz, 1H, H~ar.~), 8.14 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.80 (s, 1H, NH), 12.00 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 43.2 (CH~2~), 110.4, 113.0, 115.7, 120.7, 120.9, 121.3, 122.7, 123.0, 127.5, 127.7, 127.9, 128.0, 129.2, 134.1, 136.7, 137.7, 144.3, 146.8, 147.5 (C~ar.~, CH~ar.~, C=N), 162.4, 164.2 (2 × C=O); MS m/z: 393 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-Benzyl-5-bromo-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5**l): Yellow powder, m.p. 268--270 °C (yield 51%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.02 (s, 2H, CH~2~), 7.01 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.10 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.29 (d, *J* = 7.5 Hz, 2H, H~ar.~), 7.36--7.38 (m, 3H, H~ar.~), 7.42 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.52 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.59 (s, 1H, H~ar.~), 7.71--7.77 (m, 2H, H~ar.~), 8.44 (s 1H, H~ar.~), 11.99 (s, 1H, NH), 12.20 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 43.3 (CH~2~), 110.3, 112.1, 113.1, 114.8, 120.7, 127.7, 127.9, 128.2, 129.2, 134.1, 135.8, 136.4, 136.6, 137.6, 138.1, 142.1, 143.3, 148.7, 156.5 (C~ar.~, CH~ar.~, C=N), 161.5, 162.6 (2 × C=O); MS m/z: 471 \[M-H\]^−^; 473 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-1-Benzyl-5-chloro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5m**): Yellow powder, m.p. 268--270 °C (yield 54%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.02 (s, 2H, CH~2~), 7.06 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.11--7.13 (m, 1H, H~ar.~), 7.28--7.31 (m, 2H, H~ar.~), 7.35--7.37 (m, 3H, H~ar.~), 7.43 (d, *J* = 7.0 Hz, 1H, H~ar.~), 7.46--7.47 (m, 1H, H~ar.~), 7.52 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.71 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.32 (s, 1H, H~ar.~), 11.97 (s, 1H, NH), 12.18 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 43.3 (CH~2~), 111.7, 112.5, 112.9, 113.1, 120.7, 121.6, 127.5, 127.7, 127.9, 128.0, 128.2, 129.2, 135.9, 136.4, 137.6, 138.1, 141.7, 144.4, 149.6 (C~ar.~, CH~ar.~, C=N), 159.7, 161.6 (2 × C=O); MS m/z: 427 \[M-H\]^−^; 429 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-1-Benzyl-5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5n**): Yellow powder, m.p. 251--253 °C (yield 49%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.02 (s, 2H, CH~2~), 7.04--7.06 (m, 1H, H~ar.~), 7.09--7.13 (m, 1H, H~ar.~), 7.28--7.32 (m, 3H, H~ar.~), 7.34--7.39 (m, 4H, H~ar.~), 7.29 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.72 (s, 1H, H~ar.~), 7.75 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.13 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.91 (s, 1H, NH), 11.99 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 43.3 (CH~2~), 110.9, 111.1, 113.0, 114.4, 119.0, 120.7, 122.8, 125.3, 127.5, 127.7, 127.9, 128.0, 128.9, 129.2, 136.5, 137.6, 139.9, 140.6 (C~ar.~, CH~ar.~, C=N), 158.4 (C~1ʹ-F~, *J* = 237.9 Hz, C~ar.~), 161.9, 164.2 (2 × C=O); MS m/z: 411 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-Benzyl-5-methoxy-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5o**): Orange powder, m.p. 268--270 °C (yield 64%); ^1^H NMR (DMSO-*d*~6~) ppm: 3.81 (s, 3H, OCH~3~), 4.99 (s, 2H, CH~2~), 6.95 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.02 (dd, *J* = 2.0, 8.5 Hz, 1H, H~ar.~), 7.10 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.26--7.31 (m, 2H, H~ar.~), 7.34--7.38 (m, 4H, H~ar.~), 7.52 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.68 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.78 (s, 1H, H~ar.~), 11.92 (s, 1H, NH), 11.98 s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 43.1 (CH~2~), 56.4 (OCH~3~), 110.9, 113.0, 116.1, 120.7, 122.8, 125.2, 127.6, 127.7, 127.9, 128.0, 129.2, 129.3,136.7, 136.8, 137.7, 138.0, 138.1, 144.1, 155.6 (C~ar.~, CH~ar.~, C=N), 156.5, 164.1 (2 × C=O);MS m/z: 423 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-(4-Chlorobenzyl)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5p**): Yellow powder, m.p. 261--263 °C (yield 65%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.02 (s, 2H, CH~2~), 7.06 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.10--7.14 (m, 1H, H~ar.~), 7.19--7.21 (m, 1H, H~ar.~), 7.28--7.32 (m, 1H, H~ar.~), 7.40--7.44 (m, 3H, H~ar.~), 7.51 (d, *J* = 8.0 Hz, 2H, H~ar.~), 7.65 (s, 1H, H~ar.~), 7.72--7.75 (m, 1H, H~ar.~), 7.77 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.15 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.81 (s, 1H, NH), 11.99 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 42.6 (CH~2~), 110.9, 113.0, 119.9, 123.1, 125.2, 125.4, 127.5, 129.2, 129.7, 129.9, 131.9, 132.6, 132.8, 135.2, 135.7, 137.7, 138.0, 142.9, 144.1 (C~ar.~, CH~ar.~, C=N), 161.8, 164.2 (2 × C=O); MS m/z: 427 \[M-H\]^−^; 429 \[M-H+2\]^--^.

*N*′-\[(3*Z*)-1-(4-Cyanobenzyl)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5q**): Yellow powder, m.p. 266--268 °C (yield 57%); ^1^H NMR (DMSO-*d*~6~) ppm: 5.13 (s, 2H, CH~2~), 7.05 (d, *J* = 7.5 Hz, 1H, H~ar.~), 7.10--7.13 (m, 1H, H~ar.~), 7.20 (ddd, *J* = 2.0, 7.5, 7.5 Hz, 1H, H~ar.~), 7.39--7.43 (m, 1H, H~ar.~), 7.56 (d, *J* = 8.5 Hz, 2H, H~ar.~), 7.63--7.65 (m, 3H, H~ar.~), 7.77 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.84 (d, *J* = 3.0 Hz, 1H, H~ar.~), 7.85 (d, *J* = 3.0 Hz, 1H, H~ar.~), 8.17 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.82 (s, 1H, NH), 11.99 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 42.9 (CH~2~), 110.8, 110.9, 113.0, 115.8, 119.9, 120.7, 122.7, 123.2, 125.4, 127.1, 127.5, 128.6, 128.8, 133.1, 133.2, 137.7, 138.0, 141.9, 142.5, 142.8 (C~ar.~, CH~ar.~, 2 × CN), 161.9, 164.2 (2 × C=O); MS m/z: 418 \[M-H\]^--^.

*N*′-\[(3*Z*)-1-(4-Methylbenzyl)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5r**): Yellow powder, m.p. 256--258 °C (yield 40%); ^1^H NMR (DMSO-*d*~6~) ppm: 2.27 (s, 3H, CH~3~), 4.97 (s, 2H, CH~2~), 7.04 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.10--7.13 (m, 1H, H~ar.~), 7.16 (d, *J* = 8.5 Hz, 2H, H~ar.~), 7.27 (d, *J* = 8.5 Hz, 2H, H~ar.~), 7.29--7.34 (m, 1H, H~ar.~), 7.41--7.44 (m, 1H, H~ar.~), 7.52 (d, *J* = 8.5 Hz, 1H, H~ar.~), 7.65 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.13 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.80 (s, 1H, NH), 12.00 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 21.1 (CH~3~), 43.0 (CH~2~), 110.4, 113.0, 115.7, 120.7, 122.7, 123.0, 125.2, 127.0, 127.5, 127.7, 127.9, 129.1, 129.2, 129.8, 132.9, 133.6, 137.2, 137.7, 144.3 (C~ar.~, CH~ar.~, C=N), 162.5, 164.1 (2 × C=O); MS m/z: 407 \[M-H\]^--^.

*N*′-\[(3*Z*)-2-Oxo-1-phenyl-1,2-dihydro-3*H*-indol-3-ylidene\]-1*H*-indole-2-carbohydrazide (**5s**): Yellow powder, m.p. 277--279 °C (yield 55%); ^1^H NMR (DMSO-*d*~6~) ppm: 6.84 (d, *J* = 8.0 Hz, 1H, H~ar.~), 7.11--7.14 (m, 1H, H~ar.~), 7.24--7.31 (m, 2H, H~ar.~), 7.44--7.47 (m, 1H, H~ar.~), 7.50--7.54 (m, 4H, H~ar.~), 7.61--7.64 (m, 2H, H~ar.~), 7.58 (s, 1H, H~ar.~), 7.74 (d, *J* = 8.0 Hz, 1H, H~ar.~), 8.23 (d, *J* = 7.5 Hz, 1H, H~ar.~), 11.89 (s, 1H, NH), 12.01 (s, 1H, NH); ^13^C NMR (DMSO-*d*~6~) ppm: 110.1, 113.0,115.7, 120.7, 122.8, 123.5, 125.2, 127.2, 127.4, 127.5, 128.9, 130.2, 133.1, 134.2, 135.5, 137.3, 137.7, 141.8, 145.1 (C~ar.~, CH~ar.~, C=N), 162.9, 163.4 (2 × C=O); MS m/z: 379 \[M-H\]^--^.

### Pharmacological Evaluation {#S0002-S2001-S3003}

Pharmacological assessment of the title compounds **5a--s** was carried out using previously reported protocols[@CIT0039],[@CIT0040] and they are provided as [[Supporting materials](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}. The human cancer cell lines were procured commercially from the American Type Culture Collection.

Western Blot Analysis {#S0002-S2002}
---------------------

### Materials {#S0002-S2002-S3001}

Immunoblotting detection was performed with antibodies from Abcam against cyclin E1(clone number HE12, catalog number ab3927), cyclin D1 (clone number EP272Y, catalog number ab40754), cyclin B1 (clone number Y106, catalog number ab32053), β actin (clone number mAbcam8226, catalog number ab8226), BTG1 (clone number EPR8274(2), catalog number ab151740), BAX (clone number 2D2, catalog numberab77566), bcl-2 (clone number E17, catalog number ab32124), and caspase-3 (catalog number ab13847).

### Methods {#S0002-S2002-S3002}

A-549 non-small cell lung cancer (NSCLC) cells were plated in 25-cm^2^ culture dishes at a seeding density of 5 × 10^4^/dish before treatment with compound **5m** for 24, 48, and 72 h. Whole cell lysates were prepared using radioimmunoprecipitation assay buffer (Sigma-Aldrich, MO, USA). Protein concentrations were determined using the DC Protein Assay Kit (Bio-Rad, CA, USA). Twenty micrograms of treated and control lysates were loaded in each well of 4--20% Mini-Protean TGX Gels (Bio-Rad) for electrophoresis and then transferred to a polyvinylidene difluoride membrane (Bio-Rad). The membrane was blocked with 5% (w/v) skimmed milk prepared in Tris-buffered saline and Tween 20, incubated with primary antibodies overnight at 4 °C, washed, and then incubated with a secondary, horseradish peroxidase-coupled anti-mouse or anti-rabbit antibody. Bands were visualized with a Western Bright ECL Kit for 5000 cm^2^ Membrane and Blue Basic Autoradiography Film (BioExpress, CA, USA).

Results and Discussion {#S0003}
======================

Chemistry {#S0003-S2001}
---------

The chemical structures of the title compounds **5a--s** and their intermediates are shown in [Scheme 1](#SCH0001). The free carboxylic group of indole-2-carboxylic acid (**1**) was esterified, which resulted in the corresponding methyl ester **2**.[@CIT0041] Subsequently, compound **2** was subjected to hydrazinolysis with hydrazine hydrate, thereby forming the acid hydrazide **3**.[@CIT0042] The target indole--isatin conjugates **5a--s** were respectively prepared by reacting the acid hydrazide **3** with the appropriate isatin derivatives **4a--n** in ethanol-containing drops of acetic acid. The stereochemistry of the title conjugates **5a--s** was assigned the (*Z*)-configuration, based on the previously documented X-ray results of structurally related analogous compounds.[@CIT0043],[@CIT0044] Scheme 1Preparation of compounds **5a--s**. Reagents and conditions: (i) Few drops of concentrated sulfuric acid, absolute methanol, reflux, 4 h; (ii) H~2~N-NH~2~•H~2~O, absolute methanol, reflux, 2 h; (iii) Few drops of glacial acetic acid, absolute ethanol, reflux, 4 h.

Pharmacological Investigations {#S0003-S2002}
------------------------------

### Antiproliferative Activity {#S0003-S2002-S3001}

The cell growth-inhibitory activities of nineteen conjugates **5a--s** were evaluated with human breast (ZR-75), colon (HT-29) and lung (A-549) tumor cells. Each test compound was assessed at 30 µM in quadruplicate ([Table 1](#T0001){ref-type="table"}). The title compounds **5a--s** displayed average antiproliferative activities against the ZR-75, HT-29, and A-549 cell lines of 20.3 to 95.9%. Table 1Antiproliferative Activities (Cell Growth-Inhibitory Activities at a Concentration of 30 µm) of Compounds **5a--s** and Sunitinib Against the Indicated Cell LinesCompound No.HT-29ZR-75A-549Average Growth Inhibition %**5a**75.4 ± 3.557.7 ± 21.790.9 ± 6.280.7**5b**64.5 ± 6.758.9 ± 13.577.0 ± 9.966.8**5c**29.4 ± 21.453.9 ± 9.560.6 ± 22.347.9**5d**13.9 ± 16.140.0 ± 8.76.9 ± 18.920.3**5e**36.5 ± 8.365.9 ± 8.085.3 ± 11.262.6**5f**78.5 ± 2.873.1 ± 9.894.9 ± 4.782.2**5g**95.2 ± 4.390.2 ± 5.197.4 ± 3.994.3**5h**92.4 ± 5.281.8 ± 8.595.8 ± 4.590.0**5i**91.3 ± 5.478.8 ± 2.390.3 ± 9.386.8**5j**90.8 ± 5.582.5 ± 9.097.4 ± 3.990.2**5k**92.7 ± 2.986.6 ± 3.398.4 ± 2.092.6**5l**94.7 ± 2.979.9 ± 8.896.1 ± 4.690.2**5m**94.3 ± 3.183.8 ± 5.299.7 ± 0.792.6**5n**94.3 ± 1.677.5 ± 8.399.1 ± 1.190.3**5o**94.0 ± 4.893.8 ± 5.197.4 ± 2.995.1**5p**93.7 ± 4.289.0 ± 2.096.9 ± 3.693.2**5q**81.6 ± 5.475.4 ± 12.594.6 ± 2.383.9**5r**91.1 ± 4.279.1 ± 6.491.9 ± 4.687.4**5s**97.0 ± 2.292.2 ± 7.298.5 ± 2.095.9Sunitinib59.5 ± 2.390.7 ± 4.585.7 ± 2.778.7

[Table 2](#T0002){ref-type="table"} shows the IC~50~ (inhibitory concentration 50%) values determined for compounds **5a--s** against the tested human cancer cell lines. Compound **5m** had an average IC~50~ value of 1.17 µM against the tested human cancer cell lines, making it the most active candidate, with a potency approximately seven-fold greater than that of sunitinib (average IC~50~ value of 8.11 µM). Consequently, further pharmacological profiling was conducted with compound **5m** to better understand the potential antiproliferative mechanism of compounds **5a--s**.Table 2The IC~50~ Values of Compounds **5a--s** and Sunitinib Against the Tested Cell LinesCompound No.IC~50~ (µM)Average IC~50~ (µM)HT-29ZR-75A-549**5a**19.74 ± 1.9522.73 ± 5.7112.98 ± 2.4618.48**5b**21.93 ± 1.2921.92 ± 4.9316.01 ± 2.2619.95**5c**\>3018.01 ± 18.4719.68 ± 5.20\>22.56**5d**\>30\>30\>30\>30**5e**\>3017.87 ± 7.246.68 ± 1.5218.18**5f**12.88 ± 1.031.53 ± 31.54.04 ± 0.836.15**5g**3.68 ± 0.291.01 ± 3.281.49 ± 0.152.06**5h**5.67 ± 0.430.84 ± 7.652.13 ± 0.422.88**5i**8.92 ± 0.674.31 ± 7.982.82 ± 0.305.35**5j**5.73 ± 0.671.48 ± 7.061.93 ± 0.273.05**5k**6.19 ± 1.581.12 ± 3.051.06 ± 0.372.79**5l**2.26 ± 0.330.70 ± 12.040.65 ± 0.121.20**5m**2.02 ± 0.360.74 ± 0.880.76 ± 0.121.17**5n**3.50 ± 0.492.10 ± 3.151.41 ± 0.212.34**5o**2.28 ± 0.220.86 ± 0.760.64 ± 0.241.26**5p**2.64 ± 0.271.30 ± 0.581.05 ± 0.151.66**5q**8.11 ± 1.271.51 ± 5.032.13 ± 0.493.92**5r**2.45 ± 0.321.28 ± 12.440.64 ± 0.611.46**5s**6.34 ± 0.761.32 ± 2.892.41 ± 0.293.36Sunitinib10.14 ± 0.88.31 ± 2.45.87 ± 0.38.11[^1]

Structure Activity Relationship {#S0003-S2003}
-------------------------------

The title compounds **5a--s** are structurally classified into five groups namely, *N***--**unsubstituted derivatives **5a--e**, *N***--**methyl derivatives **5f--j**, *N***--**benzyl derivatives **5k--o**, *N***--**4**--**substituted benzyl derivatives **5p--r**, and *N***--**phenyl derivative **5s**. In the first group **5a--e**, compound **5e**, bearing a methoxy substituent in the five position of the isatin nucleus, is the most active congener with an average IC~50~ value of 18.18 µM. Compound **5g**, in the second group **5f--j**, have a bromo substituent in the five position of the isatin ring and it showed an average IC~50~ value of 2.06 µM being nearly four times more potent than sunitinib (average IC~50~ value of 8.11 µM). The third group **5k--o** seems to be the best group with an average IC~50~ range of 1.17--2.79 µM in which compound **5m**, bearing 5**--**chloroisatin fragment, is the most active congener with an average IC~50~ value of 1.17 µM being about sevenfold more potent than sunitinib. Moreover, the in vitro antiproliferative activity of the fourth group **5p--r** is in the following order **5r** ˃**5p**˃**5q** with an average IC~50~ range of 1.46--3.92 µM. Compound **5s**, bearing *N***--**phenylisatin scaffold displayed good in vitro antiproliferative activity with an average IC~50~ value of 3.36 µM ([Table 2](#T0002){ref-type="table"}). In conclusion, the *N***--**benzyl moiety on the isatin residue seems to be the favorable substituent to get good in vitro antiproliferative activity of this class of compounds.

Effects on Cell-Cycle Progression {#S0003-S2004}
---------------------------------

The influence of compound **5m** on different aspects of cell-cycle progression was investigated with the A-549 cell line based on the total DNA content of each cell. Additionally, immunofluorescent imaging of the phosphorylated retinoblastoma (Rb) protein was performed over the concentration range, 0.05--100 µM. A significant dose-dependent decrease in the total cell number ([Figure 2](#F0002){ref-type="fig"}) was noted after treatment with compound **5m** for 48 h (IC~50~ value = 1.38 µM; [Table 3](#T0003){ref-type="table"}). Figure 2Dose-dependent reductions in the numbers of adherent cells. A-549 NSCLC cells were treated for 24 or 48 h, as indicated, followed by fixation and addition of the fluorescent label. Values are presented as the average number of cells per 4 fields within each well. Table 3IC~50~ Values for the Reductions in Total Cell Numbers and the Effects of Compound **5m** and Sunitinib on Cell-Cycle ProgressionCompound No.IC~50~ (µM) for Reductions in the Total Cell NumbersIC~50~ (µM) for the Reduction of Rb PhosphorylationEffects on Cell-Cycle Progression24 h48 h24 h48 h**5m**1.77 ± 1.321.38 ±0.392.52 ± 0.2012.15 ± 3.74G1 phase increased, G2/Mphases decreasedSunitinib12.54 ± 9.833.48 ± 0.614.37 ± 0.246.27 ±0.36G1 phase decreased, G2/Mphase increased[^2]

In addition, the percentage of cells in G1 phase increased and the percentages of cells in the S and G2/M phases concomitantly decreased after treatment with compound **5m**. This finding suggests that the ability of compound **5m** to influence cell proliferation could be ascribed to decreased cell-cycle progression. Conversely, sunitinib treatment resulted in a reduced percentage of cells in G1 phase and a concomitant increase in cells in S or G2/M phase. G2 arrest could be regarded as a checkpoint blockade. Mitotic arrest may, in some instances, result in mitotic catastrophe and subsequent programmed death of cells with multiple or aberrant nuclei.

Moreover, both sunitinib and **5m** caused a substantial dose-dependent decrease in the extent of Rb protein phosphorylation ([Figure 3](#F0003){ref-type="fig"}), suggesting the possibility that the antiproliferative activity of compounds with isatin fragments can be attributed to their effect on cyclin-dependent kinases. Compound **5m** had an IC~50~ value of 2.52 µM after 24 h, indicating that it was \~1.7-fold more potent than sunitinib ([Table 3](#T0003){ref-type="table"}). Treatment with compound **5m** did not affect the extent of P-Tyr. Figure 3Dose-dependent reductions in Rb phosphorylation. A-549 NSCLC cells were treated for 24 or 48 h (as indicated), fixed, and subjected to quantitative indirect immunofluorescence and image analysis.

Western Blot Analysis {#S0003-S2005}
---------------------

Data from a previous study revealed a correlation between the antiproliferative marker, B cell translocation gene 1 (BTG1), and the inhibition of proliferation in lung cancer, which suggests that compound **5m** most likely induces cycle arrest during G1 phase.[@CIT0045] Treatment with compound **5m** increased BTG1 expression ([[Figure S1](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}), confirming its potential to act as an antiproliferative agent. To confirm the influence of compound **5m** on cell-cycle progression, the expression levels of different cell cycle-related proteins were examined using Western blot analysis. As depicted in [[Figure S2](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}, compound **5m** regulated cell cycle-related proteins and activated cyclin-dependent kinase 1 (cdc-2) via phosphorylation at Tyr 15.[@CIT0046] Although cell-cycle analysis revealed an increase in the G1 population after treatment with compound **5m**, the ability of **5m** to upregulate the G2/M phase-related proteins, cyclin B1 and p-cdc2 ([[Figure S2](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}), was interesting. Ultimately, these findings suggest that cell-cycle arrest after treatment with **5m** can occur during both G1 and G2 phases.[@CIT0047],[@CIT0048]

Many anticancer agents are designed to cause DNA damage and, consequently, apoptosis.[@CIT0049] Hence, the ability of compound **5m** to inhibit cell proliferation by inducing apoptosis was also examined. Compound **5m** activated caspase-3, with increased production of cleaved caspase-3 within 24 h of treatment ([[Figure S3](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}). The expression levels of the pro-survival protein encoded by the B-cell lymphoma/leukemia-2 (Bcl-2) gene and the pro-apoptotic protein encoded by the Bcl-2-associated X protein (BAX) gene were also evaluated. Treatment with compound **5m** increase BAX expression but had no obvious effect on Bcl-2 expression ([[Figure S3](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}). The altered BAX/BCL-2 ratio after treatment with **5m** suggests the involvement of the intrinsic apoptosis pathway.

Selectivity {#S0003-S2006}
-----------

The selectivity of compound **5m** was tested using three non-tumorigenic cell lines. IEC-6 cells obtained from rat intestines manifested both morphologic and karyotypic properties of normal intestinal epithelial cells.[@CIT0050] Cultures obtained from human fibrocystic mammary tissue (MCF-10A) are non-tumorigenic and display characteristics similar to primary cultures of breast tissue, including dome formation.[@CIT0051] Fibroblasts obtained from the embryonic tissue of mice (Swiss 3t3 fibroblasts) are both non-tumorigenic and contact-inhibited.[@CIT0052] A-549 NSCLC cells were included for comparison. The antiproliferative activities of compound **5m** and sunitinib were assessed in quadruplicate at a maximum concentration of 25 µM and then at 10 serially diluted concentrations. Compound **5m** inhibited cell growth (\>50%) in both normal and tumor cell lines. However, compound **5m** exhibited a 2.6-fold selectivity value, whereas sunitinib displayed a 1.4-fold selectivity value ([Figure 4](#F0004){ref-type="fig"} and [Table 4](#T0004){ref-type="table"}). Figure 4Tumor selectivity. A-549 NSCLC cells and non-tumorigenic cells derived from intestine, breast, and fibroblasts were treated for 72 h, as indicated, for use in a luminescence-based, growth-inhibition assay. Table 4Selectivity of Compound **5m** and Sunitinib Against Tumor and Non-Tumorigenic Cell LinesCompound No.IC~50~ (µM)Mean Tumor SelectivityIntestine IEC-6Breast MCF-10AFibroblast Swiss 3t3NSCLC A-549**5m**4.94 ± 0.822.00 ± 0.243.49 ± 1.141.33 ± 0.472.6Sunitinib3.06 ± 0.544.07 ± 0.234.43 ± 0.754.56 ± amb1.4[^3]

Multidrug-Resistant Lung Cancer Cell Line {#S0003-S2007}
-----------------------------------------

The antiproliferative activity of compound **5m** was examined against a sensitive NSCLC cell line (A-549) and a multidrug-resistant lung cancer cell (NCI-H69AR) expressing the ABCC1 efflux pump protein. Both compound **5m** and sunitinib were tested in quadruplicate at a maximum concentration of 25 µM, and then at 10 serially diluted concentrations. Compound **5m** inhibited growth in both cell lines, with an IC~50~ value of 1.33 µM in A-549 cells ([Figure 5](#F0005){ref-type="fig"} and [Table 5](#T0005){ref-type="table"}). The H69AR cells were \~19-fold less sensitive, as compound **5m** could be effluxed by the ABCC1 pump protein. Additionally, a lesser degree of sunitinib resistance (1.9-fold less sensitivity) was found in H69AR cells. Figure 5Evaluation of susceptibility to efflux. A-549 NSCLC cells and NCI-H69AR cells expressing the ABCC1 (MRP1) multi-drug resistance efflux transporter were treated for 72 h, as indicated, for use in a luminescence-based, growth-inhibition assay. Table 5Antiproliferative Activities of Compound **5m** and Sunitinib Against Sensitive (a-549) and Resistant (NCI-H69AR) Cell LinesCompound No.IC~50~ (µM)Fold-ResistanceSensitive A-549Resistant NCI-H69AR**5m**1.33 ± 0.47\>25\>19.2Sunitinib4.565.8 ± 0.521.9[^4]

Cell Viability Assay Using HEK 293 Cell Line {#S0003-S2008}
--------------------------------------------

Cell viability assay for compound **5m** showed no apparent toxicity towards human embryonic kidney (HEK) 293 cells following 24 hrs exposure to different **5m** concentrations, indicated by percent viability ranging from 93.72±0.68 to 98.67±0.39. Furthermore, there was no significant change in viability after longer exposure time to **5m** up to 72 hrs.

In Silico Predictions of ADME Properties of Compounds 5a-s {#S0003-S2009}
----------------------------------------------------------

In silico ADME (absorption, distribution, metabolism and excretion) predictions as well as some pharmacokinetic characteristics of the target compounds **5a--s** are presented in [[Table S1](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul} which are calculated according to the literature methods.[@CIT0053],[@CIT0054] All the title compounds **5a--s** follow the Lipinski's rule of 5 (RO5) where log *P* values lie between 2.2--4.2 (\<5), molecular weight range 304--473 (\<500), hydrogen bond acceptor range 3--4 (\<5), and hydrogen bond donor range 2--3 (\<5), indicating that these compounds might not be expected to cause problems with oral bioavailability. In addition, compound **5a--s** exhibited topological polar surface area (TPSA) range 77.6--101.4 Å^2^ (\<140 Å^2^), denoting good transport through cellular plasma membranes. In summary, compounds **5a--s** displayed no violations to RO5 criteria suggesting their liability to be new orally bioavailable antiproliferative candidates.

Conclusion {#S0004}
==========

Herein, we identified the newly synthesized isatin-indole molecular hybrids **5a--s** with various spectroscopic approaches and estimated their potentials as antiproliferative agents in vitro. Compound **5m** displayed promising in vitro antiproliferative potential against three human cancer cell lines. With an average IC~50~ value of 1.17 µM, this compound had a seven-fold greater potency than sunitinib (IC~50~ = 8.11 µM). By deriving its pharmacological profile, we sought to characterize the mechanisms underlying the antiproliferative activities of compounds **5a--s**. We found reduced percentages of cells in S and G2/M phases, an increased percentage of cells in G1 phase, and a significant dose-dependent decrease in the extent of Rb protein phosphorylation. Furthermore, Western blot analysis confirmed the extents of BTG1, cyclin B1, cyclin D1, and p-cdc2 upregulation caused by compound **5m**. Within 24 h of cell treatment, compound **5m** increased BAX expression and activated caspase-3, as indicated by the observed increase in cleaved caspase-3 levels. ADME predictions for compounds **5a--s** might help in further development of new anticancer agents with favorable oral bioavailability. Based on the findings presented herein, these lead compounds can be utilized in preclinical studies in the field of cancer chemotherapy.
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Supporting Materials {#S0005}
====================

Detailed protocols for the pharmacological evaluation of the title compounds **5a--s**, Western blot results for compound **5m** ([[Figures S1](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}--[[S3](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}), and ADME Table ([[Table S1](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}) are provided as [[Supporting materials](http://www.dovepress.com/get_supplementary_file.php?f=227862.docx)]{.ul}.
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[^1]: **Abbreviation:** IC~50~, inhibitory concentration 50%.

[^2]: **Abbreviation:** IC~50~, inhibitory concentration 50%.

[^3]: **Abbreviations:** IC~50~, inhibitory concentration 50%; IEC, intestinal epithelial cell; MCF, Michigan cancer foundation; 3T3, 3-day transfer, inoculums 3×10^5^ cells; NSCLC, non-small cell lung cancer.

[^4]: **Abbreviation:** IC~50~, inhibitory concentration 50%.
